BG62985B1 - Метод за диагностика и лечение на плоскоклетъченрак - Google Patents

Метод за диагностика и лечение на плоскоклетъченрак Download PDF

Info

Publication number
BG62985B1
BG62985B1 BG102513A BG10251398A BG62985B1 BG 62985 B1 BG62985 B1 BG 62985B1 BG 102513 A BG102513 A BG 102513A BG 10251398 A BG10251398 A BG 10251398A BG 62985 B1 BG62985 B1 BG 62985B1
Authority
BG
Bulgaria
Prior art keywords
antibody
lymph node
node metastasis
biwa
amino acid
Prior art date
Application number
BG102513A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102513A (en
Inventor
Karl-Heinz Heider
Guenther Adolf
Elinborg Ostermann
Erik Patzelt
Marlies Sproll
Original Assignee
Boehringer Ingelheim International Gmbh
Forschungszentrum Karlsruhe Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545472A external-priority patent/DE19545472A1/de
Application filed by Boehringer Ingelheim International Gmbh, Forschungszentrum Karlsruhe Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of BG102513A publication Critical patent/BG102513A/xx
Publication of BG62985B1 publication Critical patent/BG62985B1/bg

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BG102513A 1995-12-06 1998-06-05 Метод за диагностика и лечение на плоскоклетъченрак BG62985B1 (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19545472A DE19545472A1 (de) 1995-12-06 1995-12-06 Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
DE19615074 1996-04-17
PCT/EP1996/005448 WO1997021104A1 (de) 1995-12-06 1996-12-05 Verfahren zur diagnose und therapie von plattenepithelkarzinomen

Publications (2)

Publication Number Publication Date
BG102513A BG102513A (en) 1999-02-26
BG62985B1 true BG62985B1 (bg) 2000-12-29

Family

ID=26020988

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102513A BG62985B1 (bg) 1995-12-06 1998-06-05 Метод за диагностика и лечение на плоскоклетъченрак

Country Status (26)

Country Link
EP (1) EP0865609B1 (da)
JP (1) JP2000502067A (da)
KR (1) KR100473824B1 (da)
CN (1) CN1151377C (da)
AR (1) AR004360A1 (da)
AT (1) ATE235056T1 (da)
AU (1) AU726704B2 (da)
BG (1) BG62985B1 (da)
BR (1) BR9611901A (da)
CA (1) CA2239709A1 (da)
CO (1) CO4520233A1 (da)
CZ (1) CZ174198A3 (da)
DE (1) DE59610248D1 (da)
DK (1) DK0865609T3 (da)
EE (1) EE03783B1 (da)
ES (1) ES2190484T3 (da)
HK (1) HK1011560A1 (da)
MX (1) MX9804459A (da)
NO (1) NO319903B1 (da)
NZ (1) NZ324314A (da)
PL (1) PL184521B1 (da)
PT (1) PT865609E (da)
SK (1) SK284378B6 (da)
TR (1) TR199801027T2 (da)
UY (1) UY24389A1 (da)
WO (1) WO1997021104A1 (da)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2806512C1 (ru) * 2023-02-09 2023-11-01 Алексей Иванович Загорулько Способ лечения неоперабельного плоскоклеточного рака головы и шеи

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947496B2 (en) * 1999-10-08 2011-05-24 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20050100542A1 (en) * 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US7189397B2 (en) * 1999-10-08 2007-03-13 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
EP1258255A1 (en) * 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
CA2443437A1 (en) * 2001-05-18 2002-11-28 Boehringer Ingelheim International Gmbh Antibodies specific for cd44v6
EP1391213A1 (en) * 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
EP1417974A1 (en) * 2002-11-08 2004-05-12 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and radiotherapy
JP5763105B2 (ja) * 2010-02-04 2015-08-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体
US9218450B2 (en) 2012-11-29 2015-12-22 Roche Molecular Systems, Inc. Accurate and fast mapping of reads to genome
EP3755717A4 (en) * 2018-02-22 2022-01-26 Multitude Inc. THERAPEUTIC ANTIBODIES AND ASSOCIATED USES
WO2023227644A2 (en) 2022-05-25 2023-11-30 Akiram Therapeutics Ab Binding protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000658A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6
EP0767380A1 (de) * 1993-06-22 1997-04-09 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Diagnose und Analyse von Zervixkarzinomen
DE4326573A1 (de) * 1993-08-07 1995-02-23 Boehringer Ingelheim Int Durch Exon v5 des CD44-Gens kodierte Polypeptide als Targets für Immuntherapie und Immunszintigraphie von Tumoren
UA58482C2 (uk) * 1994-06-08 2003-08-15 Бьорінгер Інгельхайм Інтернаціональ Гмбх Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2806512C1 (ru) * 2023-02-09 2023-11-01 Алексей Иванович Загорулько Способ лечения неоперабельного плоскоклеточного рака головы и шеи

Also Published As

Publication number Publication date
PL327066A1 (en) 1998-11-23
AU726704B2 (en) 2000-11-16
MX9804459A (es) 1998-09-30
TR199801027T2 (xx) 1998-10-21
SK73698A3 (en) 1999-01-11
BG102513A (en) 1999-02-26
CN1151377C (zh) 2004-05-26
AU1177397A (en) 1997-06-27
EP0865609B1 (de) 2003-03-19
KR19990071952A (ko) 1999-09-27
KR100473824B1 (ko) 2005-09-30
UY24389A1 (es) 2001-10-25
EE03783B1 (et) 2002-06-17
JP2000502067A (ja) 2000-02-22
CZ174198A3 (cs) 1999-02-17
CA2239709A1 (en) 1997-06-12
EP0865609A1 (de) 1998-09-23
AR004360A1 (es) 1998-11-04
EE9800164A (et) 1998-12-15
WO1997021104A1 (de) 1997-06-12
DE59610248D1 (de) 2003-04-24
CO4520233A1 (es) 1997-10-15
SK284378B6 (sk) 2005-02-04
CN1207811A (zh) 1999-02-10
NO982588D0 (no) 1998-06-05
NO982588L (no) 1998-08-05
ES2190484T3 (es) 2003-08-01
BR9611901A (pt) 1999-03-02
DK0865609T3 (da) 2003-06-23
HK1011560A1 (en) 1999-07-16
NO319903B1 (no) 2005-09-26
ATE235056T1 (de) 2003-04-15
NZ324314A (en) 2000-02-28
PT865609E (pt) 2003-08-29
PL184521B1 (pl) 2002-11-29

Similar Documents

Publication Publication Date Title
KR100379217B1 (ko) CD44v6에대한모노클로날항체
EP3252076B1 (en) Diagnostic use of antibodies against ror-1 protein
AU2011200789B2 (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
JP2660241B2 (ja) モノクロナール抗体
AU2005226797B2 (en) Cytotoxicity mediation of cells evidencing surface expression of CD44
AU2007218962A1 (en) Cytotoxicity mediation of cells evidencing surface expression of TROP-2
JP2007530458A (ja) 癌疾患修飾抗体
JP2010190572A (ja) ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
MX2011004684A (es) Anticuerpos que bloquean espicificamente la actividad biologica de un antigeno de tumor.
WO2006032127A1 (en) Cytotoxicity mediation of cells evidencing surface expression of mcsp
BG62985B1 (bg) Метод за диагностика и лечение на плоскоклетъченрак
US9040670B2 (en) Monoclonal thyroid stimulating or blocking antibodies, peptide sequences corresponding to their variable regions, and their uses in diagnostic, preventive and therapeutic medicine
US7622560B2 (en) Monoclonal antibody specific for CD43 epitope
JP2001508052A (ja) ホジキンリンパ腫（Ｈｏｄｇｋｉｎ’ｓ ｌｙｍｐｈｏｍａ）の診断および治療方法
US9746474B2 (en) Acute leukemia and lymphoblastic lymphoma-specific CD43 epitope and use thereof
RU2193779C2 (ru) Средство и способ лечения плоскоклеточного рака
AU2007218958A1 (en) Cancerous disease modifying antibody 141205-02
WO2017147247A1 (en) Anti-sas1b antibodies and methods of use
CA2374587A1 (en) Hybridomas for lung cancer marker and monoclonal antibodies thereof